Introducing Perceptic: the AI operating system for drug development

2025-10-09 · Source: Air Street Press · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Artificial Intelligence & Machine Learning · Depth: Intermediate, short

Summary

Perceptic, an AI operating system for biopharma, has launched from stealth with a \$12M seed round from Air Street Capital, Accel, and angel investors. Developed by former Palantir AIP and Life Sciences team members, Perceptic is currently utilized by multiple top-20 pharma companies, including CSL, to accelerate drug discovery, expand indications, test hypotheses, and analyze clinical data. The system integrates research, development, and clinical decision-making across the drug lifecycle through three core AI applications: Scout, which reduces external asset evaluation from a week to an hour and screens thousands of assets in minutes; PercepticOS, an intelligence layer for hypothesis testing and knowledge base creation; and Atlas, a clinical data foundation that has achieved a 50-fold increase in data extractions. This integrated approach aims to transform drug development from a linear 15-year process into an always-on, insight-driven infrastructure.

Key takeaway

For Directors of AI/ML or Research Scientists in biopharma evaluating AI solutions, Perceptic offers a unified operating system to integrate AI across the drug development lifecycle. You should consider how such a system could streamline asset evaluation, accelerate hypothesis testing, and enhance clinical data extraction, potentially transforming your organization's 15-year linear processes into an always-on, insight-driven infrastructure. This approach ensures every decision is informed by comprehensive, traceable evidence.

Key insights

AI can accelerate drug development by connecting multi-modal evidence and decisions across the entire drug lifecycle.

Principles

• AI contributions must integrate into high-stakes workflows.
• Traceability of conclusions back to evidence is critical.
• AI systems learn and gain value over time within an organization.

Method

Perceptic connects data, decisions, and context via three AI applications (Scout, PercepticOS, Atlas) that learn organizational workflows and data.

In practice

• Evaluate external assets in minutes, not weeks.
• Test hypotheses against internal and external evidence.
• Increase clinical data extraction efficiency 50-fold.

Topics

• AI Operating System
• Drug Development
• Biopharma
• Clinical Data Analysis
• Asset Evaluation
• Palantir AIP

Best for: Executive, Investor, AI Product Manager, Director of AI/ML, Research Scientist, AI Architect

Related on AIssential

• AI is reengineering drug discovery by speeding up testing and scanning petabytes of data for connections between diseases — AI significantly enhances drug discovery by analyzing vast data to predict targets, efficacy, and disease interrelationships, improving success rates.
• From Radiology to Drug Discovery, Survey Reveals AI Is Delivering Clear Return on Investment in Healthcare — Healthcare and life sciences are rapidly moving from AI experimentation to execution, driven by strong ROI and open-source adoption.
• Demis Hassabis On What AI Will Do Next — AI is evolving into a co-creative partner, poised to accelerate scientific discovery and revolutionize human health within decades.
• Tevogen Bio’s Journey to Streamlining Life-Saving Therapies — Integrating a data lakehouse architecture with ML significantly accelerates drug discovery target identification.
• He Raised $70M to Cure Every Disease With AI — AI agents, particularly specialized models, significantly accelerate scientific discovery by removing human talent bottlenecks and enabling high-throughput reasoning.
• Eli Lilly's LillyPod - 9,000 Petaflops of AI Power Just Went Live for Drug Discovery — LillyPod's deployment signals AI's readiness to meet stringent pharmaceutical regulatory standards and accelerate drug discovery.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Air Street Press.